DOJ Enforcement: Talking With US FDA Is Not Enough To Get Credit For Self-Disclosure
Executive Summary
Remediation of a problem with FDA is one factor the DOJ considers in assessing whether a company gets credit for self-disclosure of misconduct prior to a criminal investigation, but it wants companies to come directly to the department to divulge wrongdoing.
You may also be interested in...
When Should Companies Self-Disclose Potential Misconduct To DOJ?
Former DOJ official notes this can be a difficult question before government initiates an investigation unless there is an obvious problem. DOJ official describes benefits of cooperation and how data analytics have changed the way the department identifies and vets cases.
Corporations Can Avoid Guilty Pleas, Compliance Monitors Under New DOJ Policies
Deputy Attorney General Lisa Monaco says the department will not seek a guilty plea when a corporation self-discloses and fully cooperates. Prosecutors to consider whether compensation systems provide incentives to promote compliance.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.